Bepirovirsen
Chronic hepatitis B · Adults with chronic hepatitis B
GSK · GSK plc
Regulatory designations
Full timeline
7 milestonesFDA decision expected
FDA assigned an October 26, 2026 PDUFA goal date to the bepirovirsen NDA.
GSK — NDA acceptance and PDUFA date↗Detailed Phase 3 B-Well results were reported
Across B-Well 1 and B-Well 2, 19% of qualifying participants achieved functional cure at week 72 with bepirovirsen plus standard of care versus 0% with placebo plus standard of care.
GSK — Detailed B-Well 1 and B-Well 2 results↗FDA accepted the NDA with Priority Review
FDA accepted the application, granted Breakthrough Therapy designation and established the October goal date.
GSK — NDA acceptance and regulatory designations↗Both Phase 3 B-Well trials met their primary endpoints
Bepirovirsen plus standard of care produced statistically significant and clinically meaningful functional-cure rates versus standard of care alone in B-Well 1 and B-Well 2.
GSK — Positive topline B-Well results↗Related News
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
Sep 13, 2026GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
Sep 13, 2026Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
Sep 10, 2026GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
Sep 1, 2026GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data